BIG 1-12

Dit bericht delen

TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC)

Wissel inhoud

This study is coordinated and sponsored by the EORTC, in collaboration with BCG, SUCCESS, UNICANCER and under the umbrella of the Breast International Group.

Pharmaceutical partners: Roche, Janssen Diagnostics

This study is funded by an educational grant from Roche and run under BIG’s Principles of Research Conduct.

More To Explore


Panacea BIG 4-13 PANACEA stands for anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer. A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab

Read More


DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share

Read More